Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation ...

Q3 2025 Management View CEO James Caruso announced significant progress in the third quarter, emphasizing "strong ...

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today ...

CFO’S MESSAGE Calfrac generated Adjusted EBITDA of $48.5 million and net income of $4.3 million from continuing operations ...

Since then China has rapidly expanded its security activity abroad by offering foreign governments police training and ...

The latest Market Talks covering Energy and Utilities. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and ...

What could the St. Louis Cardinals have up their sleeve this offseason? If you have been following along, you likely know who the Cardinals' top two trade candi ...

Capital markets are generally efficient, and investors as a whole are not stupid — that is, there is wisdom of the crowd.

Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences' Third Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025. I ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q3 2025 Earnings Call Transcript November 12, 2025 Acurx Pharmaceuticals, Inc.

As multilateral development banks (MDBs) mark the 15th anniversary of their cross‑debarment agreement, enforcement of integrity breaches in ...